Who We Are

Jeff Davidson

Chief Executive Officer Jeff Davidson holds a B.S. in chemical engineering from Purdue University and an M.B.A. from the University of Minnesota. His 32 years of experience in industry and academia include serving as the Executive Director of the Penn State Bioprocessing Resource Center; founder and Executive Director of the Pennsylvania Biotechnology Association; publisher of Your World, a biotechnology applications magazine; founder of the Biotechnology Institute, a national biotechnology education nonprofit; and founder of BioSciEd Inc. Mr. Davidson co-founded Keystone Nano and has served as its CEO since inception.


James Adair

Chief Science Officer James H. Adair is a key creator of the Keystone Nano technology, has published extensively in materials chemistry and nanobiology subjects with over 250 publications, and holds 13 patents. He has a B.S. in Chemistry and Ph.D. in Materials Science and Engineering from the University of Florida.  Dr. Adair was a Fulbright Post-doctoral Fellow in the Royal Perth Hospital at the University of Western Australia. With more than 40 years of nanoparticle experience, he is Director of the Center for Nanomedicine and Materials and a Professor of Materials Science and Engineering, Biomedical Engineering, and Pharmacology at Penn State University. Dr. Adair is a co-founder of Keystone Nano.



Mark Kester

Chief Medical Officer Mark Kester earned his B.S. in biology and economics from the State University of New York at Stony Brook and his Ph.D. in biochemistry from SUNY at Buffalo. Following an initial faculty position at Case Western Reserve University, he moved on to Penn State University in 1998, where he served as the Passananti Professor of Pharmacology, Director of the Penn State Center for Nanomedicine and Materials and the co-leader for Experimental Therapeutics at the Hershey Cancer Institute. Dr. Kester joined the faculty at the University of Virginia in 2014 as a Professor of Pharmacology and the director of the NanoSTAR Institute. Dr. Kester is a co-founder of Keystone Nano and oversees the company’s technology development associated with medical applications.


James Sharpe

Vice President of Business Development Jim Sharpe has co-founded 3 biotechnology companies and has also been Chief Operating Officer, President or CEO of 3 biopharmaceutical companies.  He has initiated, negotiated and closed over 40 transactions valued at over $200 million including mergers, acquisitions, R&D partnerships, product development collaborations, in and out-licensing, co-marketing, distribution and manufacturing agreements.  He has also raised over $25 million in financing (capital raising) for start-up and emerging companies.  He holds a B.S. in Chemistry from Union College and an MBA in Marketing & Finance from the University of Rochester.


Mylisa Parette

Vice President of Research Mylisa Parette supports Keystone Nano’s development team, leading overall program design and analysis as well as grant writing initiatives. Dr. Parette received her B.S. in Biology / Chemistry from Towson University, a M.A.T. from Brown University and her Ph.D. in Biochemistry, Molecular Biology and Microbiology from Penn State University.  Following post-doctoral work at Penn State, she joined the Keystone Nano team as a senior researcher to develop and refine NanoJacket and NanoLiposome products and processes.  With over 9 years of experience in nano-drug development Dr. Parette has been instrumental in leading Keystone Nano’s scientific staff and has secured funding of over $2 million of non-dilutive capital for the company from the National Institutes of Health, the Pennsylvania Department of Health and the Pennsylvania NanoManufacturing Commercialization Center. She is co-inventor on several US patent applications on nano-drug delivery and actively assists with regulatory development.


Carly Carter

Team Leader Carly Carter leads the Keystone Nano’s research development team.  Dr. Carter received her B.S. in Chemistry from Penn State University in 2003 and her Ph.D. in Chemistry and Biochemistry from the University of Colorado in 2010. Dr. Carter brings considerable research experience in the field of bionanomaterials, specifically, utilizing the interactions between biological molecules and materials to develop and publish on a number of promising nanoparticle therapeutics. Among that work, she has  published work on the evolution of RNA sequences capable of mediating the formation of a material with desired properties and the development of gold nanoparticles as antimicrobials capable of overcoming multi-drug resistance.  She was also the lead author of a chapter of Nano Biotechnology Protocols published by Humana Press. Dr. Carter is leading the research initiatives of Keystone Nano providing guidance, assistance in experimental design, and program management to the research team.


Jocelyn Bassler

Senior Biological Researcher Jocelyn Bassler operates Keystone Nano’s laboratory where she specializes in liposome synthesis and development as well as cell-based assays.  She received her B.S. in Biology from Virginia Tech, also earning a minor in Entomology.  Jocelyn has over 10 years of research experience, having worked in immunology and vaccine research with Southern Research Institute for seven years before joining Keystone Nano in 2010.


Samantha Damiano

Research Chemist Samantha Damiano is a member of Keystone Nano's research development team. She has received her B.S. in Chemistry from Monmouth University in 2012 and her M.S. in Chemistry from the Pennsylvania State University in 2015. Her undergraduate research focused on the synthesis of substituted viologens through microwave-assisted processes and her thesis work pertained to the use of organophosphorus compounds to carry out synthetic methodologies. She is excited and eager to apply those skills to her new position here at Keystone Nano.